• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#Visual Abstract: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

byStudy Graphics | C.WuandConstance Wu
August 22, 2020
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared to patients treated with chlorambucil–obinutuzumab.

2. Rates of adverse events in the two treatment groups were similar.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Many patients with CLL are elderly and have clinically relevant comorbid health conditions. The BCL2 antiapoptotic protein is overexpressed in CLL, and venetoclax is an oral BCL2 homology domain 3 mimetic compound which aids to induce apoptosis in B-cells. Whether venetoclax can improve treatment efficacy in CLL patients with comorbidities while limiting toxicity is undetermined. This open-label, phase 3 trial showed progression-free survival is significantly increased in patients taking venetoclax as part of their treatment regimen. Adverse outcomes compared to the current standard treatment regimen were similar.

This study supports the use of venetoclax in CLL patients with comorbidities as it optimizes a key survival outcome while toxicity is comparable with the current treatment standard. The study is limited in its strength to detect a difference in overall survival.

Click to read the study in NEJM

RELATED REPORTS

Obinutuzumab plus standard therapy is efficacious in managing active lupus nephritis

#VisualAbstract: Obinutuzumab Plus Standard Therapy Provided Complete Renal Response in Active Lupus Nephritis

Venetoclax monotherapy effectively treats relapsed or refractory chronic lymphocytic leukemia

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BCL2chlorambucilchronic lymphocytic leukemia (CLL)Obinutuzumabvenetoclax
Previous Post

Alzheimer’s Disease imaging biomarkers slightly improve prediction of memory decline

Next Post

Quick Take: Evaluating the impact of community health volunteer home visits on child diarrhea and fever in the Volta Region, Ghana

RelatedReports

Multidrug induction therapy increases remission from lupus nephritis
Chronic Disease

Obinutuzumab plus standard therapy is efficacious in managing active lupus nephritis

May 21, 2025
#VisualAbstract: Obinutuzumab Plus Standard Therapy Provided Complete Renal Response in Active Lupus Nephritis
StudyGraphics

#VisualAbstract: Obinutuzumab Plus Standard Therapy Provided Complete Renal Response in Active Lupus Nephritis

February 21, 2025
Combined lenalidomide and rituximab dose escalation found to be safe for CLL
Chronic Disease

Venetoclax monotherapy effectively treats relapsed or refractory chronic lymphocytic leukemia

March 25, 2024
#VisualAbstract: Chronic Lymphocytic Leukemia (CLL) therapy with Ibrutinib and Venetoclax guided by measurable residual disease improves progression-free survival
StudyGraphics

#VisualAbstract: Chronic Lymphocytic Leukemia (CLL) therapy with Ibrutinib and Venetoclax guided by measurable residual disease improves progression-free survival

January 31, 2024
Next Post
Quick Take: Evaluating the impact of community health volunteer home visits on child diarrhea and fever in the Volta Region, Ghana

Quick Take: Evaluating the impact of community health volunteer home visits on child diarrhea and fever in the Volta Region, Ghana

#VisualAbstract: Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa

#VisualAbstract: Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa

UTI associated with increased risk of preeclampsia

The CREOLE trial: amlodipine and either hydrochlorothiazide or perindopril optimally lowers blood pressure in black African patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.